Chemoaffinity Agents for the Detection of Prostate Cancer


To demonstrate a new approach to imaging prostate tumors

Anticipated Impact: 

Earlier prostate cancer diagnosis and improved treatments with fewer side effects


Early prostate cancer and tumor metastasis detection are critical, but accurate and reliable imaging techniques for diagnosis remain a challenge. The researchers will image prostate tumors in animal models using radioactively-labeled inhibitors of prostate-specific membrane antigen (PSMA), a marker of prostate cancer. Their objective is to build a foundation for the development and commercialization of a new diagnostic tool for prostate cancer based on single-photon emission-computed tomography. Prostate cancer is the most common cancer in men, with incidence rates in Washington ranking 15 percent above the national average. This project could lead to better outcomes for patients in the state through earlier diagnosis and improved targeted treatment therapies.

Prostate Cancer Detection, Biomarkers, Targeted Therapy

Grant Update

Principal Investigator:
Clifford Berkman
Grantee Organization:
Washington State University
Grant Title:
Chemoaffinity Agents for the Detection of Prostate Cancer
Grant Cohort and Year:
2008 Innovative Research Projects to Improve Health and Health Care (01)
Grant Period:
12/03/2008 - 12/02/2011 (Completed)
Grant Amount:
We have successfully developed a SPECT-based imaging agent for prostate cancer that is composed of an imaging radionuclide (99Tc) and a targeting molecule specific for a protein unique to prostate tumor cells. Second generation agent are in development that are expected to be prepared more efficiently.

Impact in Washington

Location of LSDF Grantee
Locations of Collaborations/Areas of Impact

Legislative Districts:
9, 45

Health Impacts

Prostate Cancer Detection, Biomarkers, Targeted Therapy